Cart
sales@molnova.com
Sanggenol O
CAS No. 426211-27-0
Sanggenol O( ——— )
Catalog No. M38966 CAS No. 426211-27-0
Sanggenol O is an active product that can be extracted from Morus alba. Sanggenol O has hepatoprotective and neuroprotective activities with EC50s more than 80 μM in HepG2 and HT22 cells.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 25MG | Get Quote | Get Quote |
|
| 50MG | Get Quote | Get Quote |
|
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameSanggenol O
-
NoteResearch use only, not for human use.
-
Brief DescriptionSanggenol O is an active product that can be extracted from Morus alba. Sanggenol O has hepatoprotective and neuroprotective activities with EC50s more than 80 μM in HepG2 and HT22 cells.
-
DescriptionSanggenol O is an active product that can be extracted from Morus alba. Sanggenol O has hepatoprotective and neuroprotective activities with EC50s more than 80 μM in HepG2 and HT22 cells.
-
In Vitro———
-
In Vivo———
-
Synonyms———
-
PathwayOthers
-
TargetOther Targets
-
Recptor———
-
Research Area———
-
Indication———
Chemical Information
-
CAS Number426211-27-0
-
Formula Weight420.45
-
Molecular FormulaC25H24O6
-
Purity>98% (HPLC)
-
Solubility———
-
SMILES———
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Jae-Woo Jung, et al. Isoprenylated flavonoids from the root bark of Morus alba and their hepatoprotective and neuroprotective activities. Arch Pharm Res. 2015 Nov;38(11):2066-75.?
molnova catalog
related products
-
α-Glucosidase-IN-23
α-Glucosidase-IN-23 is an orally active inhibitor of α-glucosidase that can decrease blood glucose levels by inhibiting α-glucosidase (IC50 = 4.48 μM).
-
Anemarrhenasaponin A...
Anemarrhenasaponin A2 (Schidigerasaponin F2) is a steroidal saponin isolated from the rhizomes of Anemarrhena asphodeloides. Anemarrhenasaponin A2 inhibits ADP-induced platelet aggregation.
-
Oroxylin A
Oroxylin A possesses abilities of inhibiting the ATRA-induced IL-6 production via modulation of LAP/LIP/CHOP in leukemia cell lines, which could providing a therapeutic strategy for RAS.
